Insmed Incorporated

355 articles with Insmed Incorporated

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 07, 2021

  4/7/2021

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to eight new employees.

• ARIKAYCE® (amikacin liposome inhalation suspension) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with MDR

  3/23/2021

  First and Only Therapy Approved in Japan, Europe, and United States for This Difficult-To-Treat Condition

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Mar 05, 2021

  3/5/2021

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to seven new employees.

• Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

  2/25/2021

  --ARIKAYCE EU Launch Progresses, with Product Now Available and Reimbursed in Germany and the Netherlands-- --Frontline Clinical Trial Program of ARIKAYCE® (amikacin liposome inhalation suspension) in Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium avium complex (MAC) Initiated in Q4 2020--

• Insmed to Present at Two March Conferences

  2/24/2021

  Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor events: The Cowen 41 st Annual Health Care Conference on Wednesday, March 3, 2021

• Insmed to Host Conference Call to Discuss Topline Data from Treprostinil Palmitil Inhalation Powder Phase 1 Study

  2/16/2021

   Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release topline data from its Phase 1 healthy volunteer trial

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Feb 05, 2021

  2/5/2021

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 14 new employees.

• Insmed Reports Grants Under NASDAQ Listing Rule 5635(c)(4)

  12/4/2020

   Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensa

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Nov 06, 2020

  11/6/2020

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 10 new employees.

• Insmed to Present at Two November 2020 Conferences

  11/2/2020

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that management will present at the following virtual investor conferences:

• Insmed Reports Third Quarter 2020 Financial Results and Provides Business Update

  10/29/2020

  --ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $43.6 Million for Third Quarter 2020-- --Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion Granted in European Union-- --Supplemental New Drug Application (sNDA) Approved by U.S. FDA for ARIKAYCE, Adding Culture Conversion Data Beyond 12 Months to Label-- --Three Key Clinical Trials Expected to Begin by End of 2020: Phase 3 ASPEN Study of Brensocatib in Non-Cystic Fibros

• European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Treatment Options

  10/28/2020

  ARIKAYCE is the First and Only Therapy Approved in Both the European Union and United States for This Difficult-To-Treat Condition

• Insmed to Host Third Quarter 2020 Financial Results Conference Call on Thursday, October 29, 2020

  10/20/2020

   Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2020 financial results on Thursday, October 29, 2020 . Insmed management will host a conference call for investors begi

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Oct 02, 2020

  10/2/2020

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to nine new employees.

• Insmed Highlights Progress Across Portfolio and Outlines Growth Strategy at R&D Day

  9/30/2020

  Initiated Phase 1 study of treprostinil palmitil inhalation powder (TPIP); Phase 2a study in pulmonary arterial hypertension planned for 2021

• Insmed to Host R&D Day on September 30, 2020

  9/16/2020

  Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host an R&D Day on Wednesday, September 30, 2020. The event is scheduled to take place from 10:00 a.m. to 12:30 p.m. ET in a virtual format.

• 

  Clinical Catch-Up: September 7-11

  9/14/2020

  It was a busy week for clinical trial updates. Here’s a look.

• Insmed to Present at Three September Conferences

  9/9/2020

   Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor conferences: The H.C. Wainwright Annual Global Investment Conference on Monday, September 14,

• New England Journal of Medicine Publishes Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis

  9/7/2020

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that final results from the Phase 2 WILLOW study of brensocatib in patients with non-cystic fibrosis bronchiectasis were published online in the New England Journal of Medicine.

• Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sep 04, 2020

  9/4/2020

  Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 12 new employees.